Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that new long-term efficacy and safety data from the Company’s ongoing Transform-HTN open-label extension trial of the aldosterone synthase inhibitor lorundrostat will be featured in a late-breaking science presentation at the American Heart Association Scientific Sessions 2026, taking place November 6-9 in Chicago, IL.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.